NCT04005690 2026-02-27
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Recruiting
Clinical Trials
54 trialsNCT06608940 2026-02-19
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT04522544 2026-02-18
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06904170 2026-02-03
ALICE
UNICANCER
Phase 2/3 Recruiting
NCT06824363 2026-01-30
ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
University of California, Irvine
Phase EARLY_PHASE1 Not yet recruiting
NCT07174570 2026-01-28
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Emory University
Phase 2 Recruiting
NCT06855225 2026-01-14
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT06526104 2026-01-06
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT04430452 2025-12-08
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
University of California, San Francisco
Phase 2 Recruiting
NCT04238637 2025-12-05
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT06564623 2025-12-05
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT02639026 2025-11-25
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT06994299 2025-11-18
PRISM
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT06698250 2025-11-06
ZENOBIA
University of Pittsburgh
Phase 2 Recruiting
NCT06058663 2025-10-20
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Mayo Clinic
Phase 1 Recruiting
NCT04605731 2025-09-10
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06999694 2025-09-10
Proton-STRIDE
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT02962063 2025-09-05
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT05701488 2025-09-02
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT03638141 2025-08-17
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT07122089 2025-08-14
IOSPHERE
Center Eugene Marquis
Phase 2 Not yet recruiting
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT04817826 2025-06-10
INFINITY
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT06999707 2025-06-05
Photon-STRIDE
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT06911255 2025-05-14
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Seoul National University Hospital
Phase 1/2 Recruiting
NCT03212469 2025-05-08
ABIMMUNE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Completed
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT06045975 2025-04-02
DUMELEP
Assistance Publique - Hôpitaux de Paris
Phase 2 Recruiting
NCT06710223 2025-02-11
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
University of California, San Diego
Phase 1 Recruiting
NCT03802747 2024-12-09
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
University of Colorado, Denver
Phase 1 Withdrawn
NCT05027425 2024-11-22
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
University of Cincinnati
Phase 2 Active not recruiting
NCT06017297 2024-11-12
ESR-22-21719
Georgetown University
Phase 2 Withdrawn
NCT06680739 2024-11-08
SERPENTINE
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT04989218 2024-11-05
ICC
University of Alabama at Birmingham
Phase 1/2 Terminated
NCT05440864 2024-10-10
(NEOTOMA)
University Health Network, Toronto
Phase 2 Recruiting
NCT02754856 2024-10-09
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04156087 2024-09-19
MIMIPAC
University Hospital, Gasthuisberg
Phase 2 Completed
NCT05844046 2024-07-16
MONTBLANC
Ludwig-Maximilians - University of Munich
Phase 2 Recruiting
NCT03959293 2024-07-08
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Federation Francophone de Cancerologie Digestive
Phase 2 Active not recruiting
NCT04159974 2024-05-09
RICE
University of Cologne
Phase 2 Unknown
NCT03046862 2024-04-19
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
Seoul National University Hospital
Phase 2 Active not recruiting
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03751761 2024-02-28
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Asan Medical Center
Phase 1/2 Completed
NCT04988945 2023-09-06
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
The University of Hong Kong
Phase 2 Recruiting
NCT03473574 2023-06-15
IMMUCHEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT05809869 2023-04-12
Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
The University of Hong Kong
Phase 2 Recruiting
NCT03202758 2023-02-10
MEDITREME
Centre Georges Francois Leclerc
Phase 1/2 Completed
NCT03982173 2023-01-26
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT01975831 2022-10-12
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT03482102 2022-09-08
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
Phase 2 Recruiting